愛齊科技 (ALGN) 2015 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings. Welcome to the Align Technology first-quarter 2015 earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded.

    各位好。歡迎參加 Align Technology 2015 年第一季財報電話會議。此時所有與會者皆為僅收聽模式。正式簡報結束後將進行簡短的問答時段。(接線員指示)。提醒您,本次會議將被錄音。

  • I would now like to turn the conference over to your host, Shirley Stacy, Vice President Corporate Communications and Investor Relations. Thank you Miss Stacy, you may now begin.

    現在我想將會議交給本次會議主持人——企業傳播與投資人關係副總裁 Shirley Stacy。謝謝 Stacy 女士,您現在可以開始。

  • Shirley Stacy - VP IR & Corporate Communications

    Shirley Stacy - VP IR & Corporate Communications

  • Good afternoon and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me today for today's call is Tom Prescott, President and CEO, David White, CFO, and Joe Hogan, incoming President and CEO.

    各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁兼執行長 Tom Prescott、財務長 David White,以及即將上任的總裁兼執行長 Joe Hogan。

  • We issued first-quarter 2015 financial results today via Marketwire which is available on our website and investor.aligntech.com.

    我們已於今日透過 Marketwire 發布 2015 年第一季財務結果,相關內容可於我們網站及 investor.aligntech.com 查閱。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on April 30. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13605393, followed by #. International callers should dial 201-612-7415 with the same conference number.

    今天的電話會議將以音訊網路直播,並將在我們網站上存檔約 12 個月。電話重播預計於今日約美東時間下午 5:30 提供。重播將開放至 4 月 30 日美東時間下午 5:30。。如需收聽電話重播,美國境內來電者請撥 877-660-6853,會議編號 13605393,然後按 #。國際來電者請撥 201-612-7415,並使用相同的會議編號。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including without limitation statements about Align's future events, product outlook and the expected financial results for the second quarter of 2015. These forward-looking statements are only predictions and involve risks and uncertainties such that actual results may vary significantly. These and other risks are set forth in more detail in our Form 10-K for the fiscal year ended December 31, 2014. These forward-looking statements reflect beliefs, estimates and predictions as of today and Align expressly assumes no obligation to update any such forward-looking statements.

    提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括但不限於關於 Align 未來事件、產品展望,以及 2015 年第二季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性,因此實際結果可能有重大差異。這些及其他風險在我們截至 2014 年 12 月 31 日止會計年度的 Form 10-K 中有更詳細的說明。這些前瞻性陳述反映截至今日的信念、估計與預測,Align 明確表示不承擔更新任何此類前瞻性陳述之義務。

  • We have posted a set of GAAP and non-GAAP historical financial statements, including the corresponding reconciliations, and our first-quarter conference call slides on our website under quarterly results. Please refer to these files for more detailed information.

    我們已在網站「季度業績」專區發布一套 GAAP 與非 GAAP 歷史財務報表(含相對應調節表),以及第一季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。

  • With that, I'll turn the call over to Align Technology's President and CEO, Tom Prescott. Tom?

    接下來,我將把電話會議交給 Align Technology 總裁兼執行長 Tom Prescott。Tom?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Thanks Shirley. Good afternoon, everyone, and thank you all for joining us. I'm pleased to have Joe with here with us here on the call today. He doesn't officially start until June 1, so we won't make him answer any questions about the business, but he'll be happy to take a couple of your questions during Q&A about why he is so excited about joining Align.

    謝謝 Shirley。各位下午好,感謝大家加入我們。我很高興 Joe 今天也與我們一同參與電話會議。他要到 6 月 1 日才會正式上任,因此我們不會讓他回答任何關於業務的問題,但在問答環節中,他很樂意回答各位幾個問題,談談他為何對加入 Align 感到如此興奮。

  • Let me turn now to our first-quarter results. On our call today, I'll provide some financial highlights and then briefly discuss the performance of our two operating segments, Invisalign Clear Aligner and scanner and services. I'll also include some commentary on our performance with customers as well as progress in our geographies around the world.

    接下來我來談談第一季業績。在今天的電話會議中,我將提供一些財務重點,並簡要說明我們兩個營運部門——Invisalign 隱形矯正器,以及掃描儀與服務——的表現。我也會就我們與客戶的表現,以及我們在全球各地區的進展提供一些評論。

  • David will provide more detail on our financials and discuss our outlook for the second quarter. Following that, I will come back and summarize a few key points and open the call up to questions.

    David 將更詳細說明我們的財務狀況,並討論第二季展望。之後我會回來總結幾個重點,並開放提問。

  • Our first quarter was a bit stronger than we expected, getting us off to a good start to the year. This progress was driven by continued strong year-over-year growth from our international team and solid improvement in our North America business as well. We are pleased to have delivered better-than-expected results with strong revenues, margins and EPS driven primarily by higher Invisalign volume from our North American orthodontists.

    我們第一季表現比預期略強,讓我們在今年有個良好開局。這項進展主要來自國際團隊持續強勁的年對年成長,以及北美業務的穩健改善。我們很高興交出優於預期的成果:營收、毛利率與每股盈餘(EPS)表現強勁,主要由北美矯正專科醫師帶來更高的 Invisalign 出貨量所驅動。

  • Our Q1 results reflect continued execution of our strategic plan, including our three key strategic growth drivers, which are market expansion, product innovation and brand strength. I'll provide a brief update on each of these before discussing our results further.

    我們第一季的結果反映出我們持續落實策略計畫,包括三項關鍵策略成長動能:市場擴張、產品創新與品牌力。在進一步討論業績之前,我將先就這三項各自提供簡要更新。

  • Market expansion comprises the many ways we are working to expand the adult orthodontic treatment category with Clear Aligner therapy, increase our share of the teenage orthodontic market and open up new and existing markets and geographies around the world. In Q1, we brought back the Benelux countries and converted them into direct sales geographies for our EMEA region and in May, we will further expand our directly covered country markets in Asia-Pacific by adding Taiwan. As with the previous countries added, we will leverage our existing infrastructure from the adjacent country teams to build local sales coverage, drive long-term market penetration and begin to create a much stronger consumer brand for Invisalign. The very important teen segment which today is still mostly a North America market, represents approximately 3/4 of worldwide orthodontic case starts each year. Execution of our strategy is enabling us to continue to gain share against other brackets and wires players. As of Q1, more than 121,000 teenagers started treatment with Invisalign over the past 12 months, up 16.3% from the prior year in an orthodontic market that is growing in the low to mid single digits overall. With all our progress, we are far from realizing our full potential in teenage segment and are really just getting started in the EMEA and APAC regions where we are implementing focused initiatives to drive awareness and preference for Invisalign for teens.

    市場擴張涵蓋我們為擴大成人矯正治療類別(以透明矯正器療程為主)、提升青少年矯正市場占有率,以及在全球開拓新市場與既有市場/地理區域所採取的多種方式。在第一季,我們將比荷盧三國重新納入,並將其轉為 EMEA 區域的直營銷售地區;而在 5 月,我們將在亞太地區進一步擴大直營覆蓋國家市場,新增台灣。如同先前新增的國家,我們將運用鄰近國家團隊既有的基礎設施,建立在地銷售覆蓋、推動長期市場滲透,並開始為 Invisalign 打造更強的消費者品牌。極為重要的青少年區隔目前仍以北美市場為主,約占全球每年矯正病例啟動數的 3/4。我們策略的執行使我們得以持續相對於其他托槽與鋼線競爭者提升市占。截至第一季,過去 12 個月已有超過 121,000 名青少年以 Invisalign 開始治療,較前一年成長 16.3%;而整體矯正市場僅以低至中個位數成長。儘管我們已取得進展,但在青少年區隔距離完全發揮潛力仍有很大空間;在我們正推動聚焦型計畫、提升青少年對 Invisalign 的認知與偏好之 EMEA 與 APAC 地區,我們其實才剛起步。

  • Q2 marks the start of the busy summer teen orthodontic season, and we have new teen sales programs and an orchestrated marketing effort designed to increase our doctors' confidence in Invisalign while overcoming key barriers which may keep them from recommending Invisalign more often for their teenage patients. These new programs include case studies detailing how to drive increase practice growth and profit ability by integrating teen Invisalign cases, how to better utilize practice referrals and leverage Invisalign marketing and the teen confidence study.

    第二季標誌著繁忙的暑期青少年矯正旺季開始;我們推出新的青少年銷售方案與整合式行銷活動,旨在提升醫師對 Invisalign 的信心,同時克服可能使醫師較少向青少年患者推薦 Invisalign 的關鍵障礙。這些新方案包括案例研究,說明如何透過導入青少年 Invisalign 病例來推動診所成長並提升獲利能力、如何更有效運用診所轉介並善用 Invisalign 行銷資源,以及青少年信心研究。

  • Product innovation aims to create greater doctor preference for Invisalign by delivering new features and functionality to increase our doctors' confidence in treating patients with Invisalign more often and on more complex cases.

    產品創新的目標,是透過提供新功能與特性來提升醫師對 Invisalign 的偏好,進而提高醫師信心,使其更常以 Invisalign 治療患者,並能處理更複雜的病例。

  • As the science, technology and clinical capability behind Invisalign continues to evolve and expand, our ability to gain incremental share of orthodontic case starts expands with it. During Q1, we began initial commercialization activities for Invisalign G6, our solution for first pre-molar extraction cases, including speaker training and launch workshops. The initial feedback from targeted Invisalign providers shows excitement about the potential for more effective treatment of these extraction cases. This is especially true in our Asian markets where extraction cases represent over 70% of the cases presenting to the doctor.

    隨著 Invisalign 背後的科學、技術與臨床能力持續演進與擴展,我們提升矯正病例啟動數增量市占的能力也隨之擴大。在第一季,我們開始對 Invisalign G6(我們針對第一前磨牙拔牙病例的解決方案)進行初步商業化活動,包括講者訓練與上市工作坊。來自目標 Invisalign 提供者的初步回饋顯示,他們對於更有效治療這些拔牙病例的潛力感到振奮。這在亞洲市場尤其明顯,因為拔牙病例占就診病例的 70% 以上。

  • Feedback has also been very positive across Europe where orthodontists see Invisalign G6 as a significant step towards the expansion of Invisalign applicability to a broad range of increasingly complex malocclusions. While still very early in our launch process, over 220 doctors have already submitted Invisalign G6 cases. In Q2, we will begin full launch activities for Invisalign G6, including expanded training for Invisalign doctors and our sales and customer support teams. Over 3,000 customers are expected to attend Invisalign G6 live lab events across the EMEA and APAC region.

    在歐洲各地的回饋也非常正面,矯正專科醫師認為 Invisalign G6 是推動 Invisalign 適用範圍擴展至更廣泛、且日益複雜之咬合不正的重要一步。雖然我們仍處於上市流程的非常早期階段,但已有超過 220 位醫師提交 Invisalign G6 病例。在第二季,我們將開始 Invisalign G6 的全面上市活動,包括為 Invisalign 醫師以及我們的銷售與客戶支援團隊提供更擴大的訓練。預計將有超過 3,000 名客戶參加在 EMEA 與 APAC 地區舉辦的 Invisalign G6 現場實作實驗室活動。

  • During Q1, we also launched ClinCheck Pro in EMEA and APAC. This significant ClinCheck software evolution has been extremely well received and already nearly half of our customers in EMEA and APAC have now switched to the new platform, attracted by enhancements on 3-D control and efficiency.

    在第一季期間,我們也在歐洲、中東及非洲(EMEA)與亞太(APAC)地區推出了 ClinCheck Pro。這項 ClinCheck 軟體的重大演進獲得極佳回響,目前 EMEA 與 APAC 地區的客戶中,已有將近一半轉換至新平台,主要受到 3D 控制與效率提升等強化功能的吸引。

  • And finally, brand strength. The brand strength of Invisalign remains one of Align's key differentiators for both doctors and their patients.

    最後是品牌力。Invisalign 的品牌力仍是 Align 對醫師及其患者而言的關鍵差異化優勢之一。

  • Align has built a superior brand through a very integrated consumer marketing platform that includes TV, media, social networking and event marketing. Our goals are to make Invisalign a household name worldwide and to motivate consumers to insist on Invisalign for getting the healthier, more beautiful smile they've always wanted.

    Align 透過高度整合的消費者行銷平台建立了卓越品牌,涵蓋電視、媒體、社群網路與活動行銷。我們的目標是讓 Invisalign 成為全球家喻戶曉的品牌,並促使消費者為了獲得他們一直渴望的更健康、更美麗笑容,而堅持選擇 Invisalign。

  • In North America, we saw positive growth in virtually all key consumer demand metrics as a result of cross-channel marketing, efforts across TV, digital, social media and PR channels. As a result, the numbers of consumers searching for the Invisalign brand grew significantly.

    在北美,由於跨通路行銷(涵蓋電視、數位、社群媒體與公關通路)的推動,我們在幾乎所有關鍵消費者需求指標上都看到正向成長。因此,搜尋 Invisalign 品牌的消費者人數顯著增加。

  • We also had good growth in unique visitors to Invisalign.com as well as a step up in the number of doc locator searches. Our focus on social media has enabled a substantial increase in followers across Invisalign's social media properties like Facebook, Twitter and more.

    我們在 Invisalign.com 的不重複訪客數也有良好成長,且醫師查找(doc locator)搜尋次數亦有所提升。我們對社群媒體的聚焦,使 Invisalign 在 Facebook、Twitter 等社群平台上的追蹤者大幅增加。

  • As a key element in social media, we continue to see user generated content from patients describing their Invisalign journey as the top-performing content on Invisalign social channels. And in preparation for the upcoming teen orthodontic season, we will kick off one of our largest efforts of the year targeted to the mom audience promoting Invisalign Teen through our unbraced Teen Confidence campaign which leverages our teen confidence study published last year. The results of this study highlight the struggles teens have with their self-confidence during the teenage years, and that teens wearing Invisalign aligners had a 2X boost in self-esteem when compared to teens wearing metal braces.

    作為社群媒體的關鍵要素,我們持續看到由患者產生、描述其 Invisalign 歷程的使用者生成內容(UGC),是 Invisalign 社群通路上表現最佳的內容。此外,為迎接即將到來的青少年矯正旺季,我們將啟動本年度規模最大的行銷活動之一,鎖定媽媽族群,透過我們的「無鋼牙 Teen Confidence(青少年自信)」活動推廣 Invisalign Teen,並運用我們去年發表的青少年自信研究。該研究結果凸顯青少年在青春期面臨的自信困擾,且配戴 Invisalign 隱形牙套的青少年,相較於配戴金屬牙套的青少年,自尊心提升達 2 倍。

  • In EMEA, while our overall consumer programs are on a smaller scale, we have made good use of digital media to effectively reach our target audience while accelerating social media, experiential events and PR activities.

    在 EMEA,雖然我們整體消費者方案的規模較小,但我們善用數位媒體有效觸及目標受眾,同時加速社群媒體、體驗式活動與公關(PR)活動的推進。

  • We continue to drive significant increases in awareness of Invisalign year-over-year. The Invisalign EU social media community continues to grow with double the number of fans from the same period last year.

    我們持續推動 Invisalign 的知名度逐年大幅提升。Invisalign 歐盟(EU)社群媒體社群持續成長,粉絲數較去年同期增加一倍。

  • Globally as a brand, we recently celebrated the milestone of 3 million Invisalign smiles by inviting our customers, patients, consumers and employees to help spread even more smiles by providing a large donation to Operation Smile. We did this by asking everyone to do something very simple, to post a picture of their smile with the #3,000,000 smiles. And for every smile shared in this way, we would donate $1 to Operation Smile up to $1 million over the campaign. If you're not familiar with this very worthy cause, I'd like you to look into the profound impact they have on children and adults born with cleft lip and cleft palate, especially in countries with little to no access to care. The amazing things they are doing at Operation Smile need financial support to reach even more children with this life-changing procedure.

    就全球品牌而言,我們近期慶祝達成 300 萬個 Invisalign 微笑的里程碑,並邀請我們的客戶、患者、消費者與員工,透過向「微笑行動(Operation Smile)」提供大額捐款,一起傳遞更多笑容。我們的做法是請大家做一件非常簡單的事:上傳一張自己的笑容照片,並加上 #3,000,000 smiles。而每分享一個這樣的笑容,我們就會向 Operation Smile 捐出 1 美元,整個活動期間最高捐款上限為 100 萬美元。若您對這個非常值得支持的公益組織不熟悉,我希望您能了解他們對於天生唇裂與顎裂的兒童與成人所帶來的深遠影響,尤其是在幾乎沒有或完全無法取得醫療照護的國家。Operation Smile 正在做的令人驚嘆的工作,需要財務支持,才能讓更多孩子接受這項改變人生的手術。

  • You may have seen our full-page ad in the New York Times earlier to kick this effort off. To date, this has been a very successful way to engage with our community, generating thousands of posts that were seen over 9 million times across the globe.

    您可能先前已在《紐約時報》看到我們的全版廣告,用以啟動這項行動。截至目前,這是一種非常成功的社群互動方式,已產生成千上萬則貼文,並在全球累計被觀看超過 900 萬次。

  • There are plenty of highlights to share here, but since we included some details on our consumer activities in our webcast slides, I'll skip the details and let you review by yourself.

    這裡有許多亮點可分享,但由於我們已在網路直播簡報中納入部分消費者活動的細節,我就不再贅述,請各位自行查閱。

  • Taken together, these three key strategic growth drivers -- market expansion, product innovation and brand strength -- provide us with a great set of levers to build the business, giving us confidence in our plans for continued long-term growth. With these growth drivers in mind, let's talk about how we did in Q1 by sharing a few customer and geographic highlights.

    綜合而言,這三項關鍵策略性成長驅動因素——市場擴張、產品創新與品牌力——為我們提供了打造業務的絕佳槓桿,使我們對持續的長期成長計畫更具信心。基於這些成長驅動因素,接下來我們將透過分享一些客戶與地區亮點,談談第一季的表現。

  • In Q1, the North America business demonstrated continued progress. During the quarter, our practices reported solid patient traffic and procedure volumes across the board, including for Invisalign. On a sequential basis, Q1 growth was driven primarily from North American orthodontists with utilization growing to nine cases per doctor for the first time ever. This utilization increase reflects continued traction from our cycle of product innovations, including Invisalign G5 for deep bite launched early last year.

    第一季,北美業務展現持續進展。本季期間,我們的診所普遍回報穩健的患者來診量與療程量,包括 Invisalign 在內。以季對季來看,第一季成長主要由北美矯正專科醫師帶動,使用量首次提升至每位醫師 9 例。此使用量提升反映我們產品創新循環持續獲得市場牽引力,包括去年年初推出、用於深咬(deep bite)的 Invisalign G5。

  • Additionally, we believe the evolution in our go-to-market strategy as discussed in our Q4 call is creating some positive impact a little earlier than expected. We are pleased to see some initial traction and expect more meaningful contribution from these changes in the back half of the year and beyond.

    此外,我們認為如同在第四季電話會議中所討論的,我們的市場進入(go-to-market)策略演進,正比預期更早帶來一些正向影響。我們很高興看到初步成效,並預期這些變革在今年下半年及之後將帶來更具意義的貢獻。

  • Turning to our international business, Q1 Invisalign volume was down slightly on a sequential basis as expected, reflecting a seasonally slower period in the EMEA region mostly offset by higher than expected volume from Asia-Pacific. This was especially the case in China with continued growth, despite the lunar new year in mid February. On a year-over-year basis, international growth remains strong driven by continued momentum from product innovation and go-to-market expansion. Our Q1 results reflect increased adoption from our existing customer base and accelerated adoption from newly trained doctors across all international geographies and channels.

    再看國際業務,第一季 Invisalign 出貨量如預期在季對季基礎上略為下滑,反映 EMEA 地區季節性較淡的期間,而亞太地區高於預期的量大致抵銷了這一影響。其中以中國最為明顯,儘管農曆新年在 2 月中旬,仍維持持續成長。以年對年來看,國際成長仍然強勁,主要由產品創新與市場進入擴張的持續動能所驅動。我們第一季的結果反映既有客戶群採用率提升,以及在所有國際地區與通路中,新受訓醫師的採用加速。

  • In the EMEA region, Q1 Invisalign case volume increased 25.1% year-over-year, reflecting growth across all country markets, especially in Spain. We are also very pleased with the improved performance in Italy and the UK. Our new direct markets in Eastern Europe, Scandinavia and now Benelux are also generating initially high-growth levels, albeit on a small base, as our renewed focus on sales and clinical education are starting to pay off.

    在 EMEA 地區,第一季 Invisalign 病例量年增 25.1%,反映所有國家市場皆有成長,尤其是西班牙。我們也對義大利與英國表現改善感到非常滿意。我們在東歐、斯堪地那維亞,以及目前的比荷盧(Benelux)等新直營市場,也在相對較小的基期上產生初期的高成長水準;隨著我們重新聚焦於銷售與臨床教育,正開始看到成效。

  • In the APAC region, Invisalign case volume increased 37.5% year-over-year, reflecting continued strong growth across all countries. While China and Japan continue to deliver the fastest growth, we're also seeing solid execution of our growth plans in Southeast Asia and Australia and New Zealand.

    在 APAC 地區,第一季 Invisalign 病例量年增 37.5%,反映所有國家持續強勁成長。中國與日本持續貢獻最快成長之際,我們也看到在東南亞、澳洲與紐西蘭的成長計畫執行穩健。

  • Now, turning to our scanner business, in Q1, our scanner and services business revenues were down sequentially as we expected. The decrease in revenue also reflected reduced pricing offering for the current iTero scanner to bridge commercial availability for the new iTero Element scanner announced last month at the International Dental Show, IDS, in Germany.

    接著談掃描器業務,第一季我們的掃描器與服務業務營收如預期在季對季基礎上下滑。營收下滑也反映我們針對現行 iTero 掃描器提供較低的定價方案,以銜接上月在德國國際牙科展(IDS)宣布的新款 iTero Element 掃描器的商業供貨。

  • The iTero element is engineered to deliver everything that doctors appreciate about an iTero scanner except in a more compact footprint with even greater capabilities. The element's smaller design with enhanced wand, multitouch display and new image sensor is engineered to enable 20 times faster scan speed with color scanning for more precise clinical evaluation. We were excited to have the opportunity to preview the new scanner at IDS and we are pleased to be receiving very positive responses from existing iTero users as well as from potential new customers. Both are very interested in the Element's new and smaller form factor, faster scans and expanded capabilities.

    iTero Element 的設計目標,是在更精巧的機身尺寸下,提供醫師喜愛 iTero 掃描器的一切特點,並具備更強大的能力。Element 較小的設計,搭配強化的掃描棒(wand)、多點觸控顯示器與新影像感測器,旨在實現快 20 倍的掃描速度,並支援彩色掃描,以進行更精準的臨床評估。我們很高興能在 IDS 預覽這款新掃描器,也很欣慰收到現有 iTero 使用者與潛在新客戶的非常正面回饋。雙方都對 Element 更小的外型、更快的掃描速度與擴充的功能深感興趣。

  • IDS also marked the beginning of our expanding go-to-market resources in the EMEA and APAC regions for the iTero platform. We do expect initial shipments for the iTero Element intraoral scanner to begin the second half of 2015.

    IDS 也標誌著我們開始在 EMEA 與 APAC 地區擴充 iTero 平台的市場進入資源。我們預期 iTero Element 口內掃描器的初期出貨將於 2015 年下半年開始。

  • While we are proud to have the best scanner in the market with the greatest utility for our customers, we also believe there's an even greater opportunity for customers to benefit from Align Technology's open systems approach, both for our iTero scanners as well as for the Invisalign system. We have worked hard to qualify other leading intraoral scanners that have the potential capability to deliver high-quality interoperability with the Invisalign case submission process. To that end, at IDS last month, we announced interoperability for Invisalign case submission with Sirona's CEREC Omnicam. This qualification enables Invisalign providers the CEREC Omnicam, a new CEREC Ortho Software 1.1, to submit a digital impression in place of a traditional PBS impression. We look forward to working with the Sirona team to ensure their customers and patients have a great Invisalign experience.

    雖然我們很自豪能擁有市場上最好的掃描器,並為客戶提供最大的實用性,但我們也相信,客戶仍有更大的機會可從愛齊科技(Align Technology)的開放式系統策略中受益,這不僅適用於我們的 iTero 掃描器,也適用於 Invisalign 系統。我們一直努力使其他具領先地位的口內掃描器通過資格認證,這些掃描器具備與 Invisalign 病例提交流程實現高品質互通性的潛在能力。為此,我們在上個月的 IDS 上宣布,Sirona 的 CEREC Omnicam 已可用於 Invisalign 病例提交的互通。此項資格認證使使用 CEREC Omnicam 的 Invisalign 提供者,搭配新版 CEREC Ortho Software 1.1,得以以數位印模取代傳統的 PBS 印模來提交。我們期待與 Sirona 團隊合作,確保其客戶與患者都能擁有絕佳的 Invisalign 體驗。

  • And with that, I will now turn the call over to David for a review of our Q1 financial results. David?

    接下來,我將把電話會議交給 David,請他回顧我們第一季的財務結果。David?

  • David White - CFO

    David White - CFO

  • Thanks Tom. Note that this fiscal year, we are consolidating some of the supplementary product and geographic breakdowns that we provide for volumes and revenue as well as combining sales and marketing expense with general and administrative. We will continue to explain the performance of our products and geographies and include commentary as appropriate. However, we believe a consolidated view of our quarterly financials is more consistent with disclosures from our respective peer group.

    謝謝你,Tom。請注意,在本會計年度,我們將整併部分我們在出貨量與營收方面所提供的補充性產品與地理區域拆分資訊,並將銷售與行銷費用與一般及行政費用合併呈列。我們仍將持續說明各產品與各地區的表現,並在適當時提供評論。然而,我們認為,以整併後的角度呈現季度財務資訊,更符合我們同業群的揭露方式。

  • Let's review our first-quarter financial results. Revenue for the first quarter was $198.1 million, down 0.3% from the prior quarter and up 9.7% from the corresponding quarter a year ago. First-quarter Clear Aligner revenue of $187 million was up 0.3% sequentially and up 11.2% year-over-year. The slight sequential revenue growth reflected higher volume from our North American Ortho doctors, offset slightly by lower volume from our international doctors as well as lower worldwide ASPs.

    讓我們回顧第一季的財務結果。第一季營收為 1.981 億美元,較前一季下降 0.3%,較去年同期增加 9.7%。第一季透明牙套(Clear Aligner)營收為 1.87 億美元,較前一季增加 0.3%,較去年同期增加 11.2%。些微的季增主要反映北美矯正科醫師出貨量增加,但部分被國際醫師出貨量下降以及全球平均銷售價格(ASP)降低所抵銷。

  • Q1 ASPs were down sequentially $35, of which approximately $32 or $4.2 million in aggregate was related to foreign exchange rates. Our year-over-year revenue growth reflected Invisalign case volume growth across all customer channels, partially offset by lower ASPs primarily related to foreign exchange rates.

    第一季 ASP 較前一季下降 35 美元,其中約 32 美元(合計約 420 萬美元)與外匯匯率有關。我們的年增營收成長反映 Invisalign 病例量在所有客戶通路皆成長,但部分被 ASP 降低所抵銷,而 ASP 下降主要與外匯匯率有關。

  • For the first quarter, total Invisalign shipments of 130,800 cases were up 3.1% sequentially, reflecting growth from our North American orthodontists and to a lesser extent North American GP customers. Year-over-year case volume growth was 16.6%, reflecting continued strength in international as well as strong demand from our North American orthodontists.

    第一季 Invisalign 總出貨量為 130,800 例,較前一季增加 3.1%,反映北美矯正科醫師的成長,且在較小程度上也反映北美一般牙醫(GP)客戶的成長。病例量年增 16.6%,反映國際市場持續強勁,以及北美矯正科醫師需求強勁。

  • For North American orthodontists, Q1 Invisalign case volume was up 7.9% sequentially and up 17% year-over-year. For North American GP dentists, case volume was up 1.6% sequentially and 6.5% year-over-year. For international doctors, Invisalign case volume was seasonally down 0.9% sequentially and up 29% year-over-year. Q1 marks the sixth consecutive quarter of greater than 25% growth for our international region.

    就北美矯正科醫師而言,第一季 Invisalign 病例量較前一季增加 7.9%,較去年同期增加 17%。就北美一般牙醫(GP)而言,病例量較前一季增加 1.6%,較去年同期增加 6.5%。就國際醫師而言,Invisalign 病例量受季節性影響較前一季下降 0.9%,但較去年同期增加 29%。第一季是我們國際區域連續第六個季度成長率超過 25%。

  • Worldwide Invisalign utilization in Q1 was 4.5 cases per doctor, up slightly from 4.3 in Q1 last year. North American Ortho utilization of 9.0 was a new record, increasing from 8.1 in the prior year. North America GP utilization of 2.9 was flat compared with the prior year. And international doctor utilization of 4.4 was up slightly from 4.3 in the prior year.

    第一季全球 Invisalign 使用率為每位醫師 4.5 例,較去年第一季的 4.3 例略為上升。北美矯正科使用率為 9.0,創下新紀錄,較前一年 8.1 提升。北美一般牙醫(GP)使用率為 2.9,與前一年持平。國際醫師使用率為 4.4,較前一年的 4.3 略為上升。

  • In Q1, we added 2,410 new Invisalign doctors worldwide, 870 of which were new North American doctors, and 1,540 of which were new international doctors.

    第一季我們在全球新增 2,410 位 Invisalign 新醫師,其中 870 位為北美新醫師,1,540 位為國際新醫師。

  • First-quarter revenue for our scanner and services segment was $11.1 million, a decrease of 9.1% sequentially and 10.9% year-over-year. While unit sales of our scanner were slightly down relative to each period, most of the revenue decline was the result of reduced pricing for the current iTero scanner which Tom previously commented on.

    第一季我們的掃描器與服務事業部營收為 1,110 萬美元,較前一季下降 9.1%,較去年同期下降 10.9%。雖然掃描器的單位銷售量相較各期間略有下滑,但營收下滑的大部分原因是目前 iTero 掃描器的定價降低,Tom 先前已就此評論。

  • Moving on to gross margin, first-quarter gross margin was 76.3% overall, up sequentially 0.4 points and 0.3 points year-over-year. Clear Aligner gross margin for the first quarter was 79.1%, up 0.3 points sequentially and flat year-over-year. The sequential increase was primarily the result of higher volumes and seasonally lower training costs offset by lower ASPs, as mentioned. Q1 gross margin for the scanner segment was 28.3%, down 1.9 points sequentially and 5.3 points year-over-year, both as a result of lower ASPs, as previously mentioned.

    接著看毛利率,第一季整體毛利率為 76.3%,較前一季上升 0.4 個百分點,較去年同期上升 0.3 個百分點。第一季透明牙套(Clear Aligner)毛利率為 79.1%,較前一季上升 0.3 個百分點,較去年同期持平。季增主要來自出貨量提高與季節性較低的培訓成本,但部分被前述 ASP 下降所抵銷。第一季掃描器事業部毛利率為 28.3%,較前一季下降 1.9 個百分點,較去年同期下降 5.3 個百分點,兩者皆因 ASP 較低所致,如前所述。

  • Q1 operating expenses were $102.2 million, up sequentially by $3 million from $99.2 million reported in Q4. In aggregate, overall operating expenses were up by $9.8 million primarily related to increased employee headcount and compensation expense related to our annual employee performance review process, increased legal fees and investments in OSA product development which were offset in part by a benefit of $6.8 million associated with a medical device excise tax refund for a net sequential increase of $3 million.

    第一季營業費用為 1.022 億美元,較第四季報告的 9,920 萬美元季增 300 萬美元。整體而言,營業費用合計增加 980 萬美元,主要與員工人數增加、因年度員工績效考核流程而增加的薪酬費用、法律費用增加,以及對 OSA 產品開發的投資有關;其中部分被 680 萬美元的利益所抵銷,該利益與醫療器材消費稅退稅相關,因此淨季增為 300 萬美元。

  • You will recall a year ago that we had extensive discussions with the IRS in which they informed us that our Clear Aligners are not subject to this tax. Accordingly, we stopped accruing and paying this tax in March 2014. However, a refund of our 2013 payments would require separate application, review and approval. That approval was received this quarter. The after-tax benefit of this refund on EPS in the quarter was $0.06.

    各位會記得,一年前我們與美國國稅局(IRS)進行了廣泛討論,他們告知我們的透明牙套不適用此項稅負。因此,我們於 2014 年 3 月停止計提並繳納此稅。然而,2013 年已繳款項的退稅需要另行提出申請、審查並獲核准。該核准已於本季取得。本季該退稅對每股盈餘(EPS)的稅後利益為 0.06 美元。

  • On a year-over-year basis, Q1 operating expenses were up $6.7 million, which includes the benefit of the medical excise tax refund just mentioned, reflecting increased headcount and continued investment in our go-to-market activities as well as product and technology development as we talked about at length in our Q4 year-end earnings call in January.

    以年對年來看,第一季營業費用增加 670 萬美元,其中包含剛才提到的醫療消費稅退稅利益;此增幅反映員工人數增加,以及我們持續投資於市場推進(go-to-market)活動,並投入產品與技術開發,正如我們在 1 月的第四季年終財報電話會議中已詳細討論。

  • Our first-quarter operating margin was 24.7%, down 1.2 points sequentially and up 1.6 points year-over-year. First-quarter results included the aforementioned medical excise tax refund of $6.8 million, which benefited operating margins by 3.4 points. Excluding the margin benefit from this refund, operating margins were down both sequentially and year-over-year relating to new investments in our three strategic growth drivers as we previously discussed.

    第一季營業利益率為 24.7%,較前一季下降 1.2 個百分點,較去年同期上升 1.6 個百分點。第一季結果包含前述 680 萬美元的醫療消費稅退稅,使營業利益率受益 3.4 個百分點。若排除該退稅帶來的利益率提升,營業利益率無論季比或年比皆下降,原因與我們先前討論的三項策略性成長驅動因素之新增投資有關。

  • Other income and expense included $1.7 million of charges primarily related to foreign currency losses related to customer payments with the continued weakening of the euro to the US dollar comprising most of that. All together, the quarter-over-quarter impact from foreign exchange as a result of the stronger US dollar, including the decline on revenues, the benefit on our non-US dollar operating expenses, together with currency exchange losses reported in other income and expense, was $0.03 per share.

    其他收入與費用包含 170 萬美元的費用,主要與客戶付款所產生的外幣損失有關,其中大部分來自歐元兌美元持續走弱。整體而言,由於美元走強所造成的外匯季對季影響(包含營收下滑、非美元營業費用的利益,以及在其他收入與費用中認列的匯兌損失)合計為每股 0.03 美元。

  • While currency has certainly dampened to some extent our business results, we believe continued investment in our strategic growth initiatives will accelerate current-year and long-term growth where the leverage of our business model will ultimately overcome the negative impact of a stronger US dollar. In tandem with those investments, however, we do intend to begin commencing some of our current -- hedging some of our currency exposures to mitigate some of the intra-quarter volatility we have been experiencing commencing in Q2.

    雖然匯率確實在一定程度上抑制了我們的營運成果,但我們相信,持續投資於策略性成長計畫將加速本年度及長期成長,而我們商業模式的槓桿效應最終將克服美元走強的負面影響。不過,在進行這些投資的同時,我們也確實打算自第二季開始,著手對部分外匯曝險進行避險,以降低我們目前所經歷的季度內波動。

  • With regards to our first-quarter tax provision, our tax rate was 23.8%, slightly up from our 2014 tax rate due to higher permanent tax differences on certain expenses that are not deductible.

    關於我們第一季的所得稅提列,我們的稅率為23.8%,較2014年的稅率略為上升,原因是某些不可扣抵費用所產生的永久性稅務差異增加。

  • First-quarter diluted earnings per share was $0.44 compared to $0.48 reported in Q4 and $0.39 reported in the same quarter last year.

    第一季稀釋後每股盈餘為0.44美元,相較於第四季報告的0.48美元,以及去年同期報告的0.39美元。

  • Moving on to the balance sheet, for the first quarter, our Accounts Receivable balance was $138.2 million, up approximately 6.5% sequentially. Our overall DSO was 63 days, up five days sequentially and flat over the same period a year ago. Capital expenditures for the first quarter were $15.6 million, primarily relating to a second facility purchased in Juarez, Mexico for liner fabrication as well as manufacturing, equipment and fittings costs for that facility as we add additional capacity, as well as additional costs capitalized on our enterprise systems project.

    接著看資產負債表,第一季我們的應收帳款餘額為1.382億美元,較前一季約增加6.5%。我們整體DSO為63天,較前一季增加5天,且與一年前同期間持平。第一季資本支出為1,560萬美元,主要與在墨西哥華雷斯(Juarez)購置第二座用於內襯(liner)製作的廠房相關,以及隨著我們增加產能而為該廠房投入的製造、設備與裝配成本,另亦包含我們企業系統專案中資本化的額外成本。

  • Cash flow from operations for the first quarter was $35.6 million. And free cash flow for the first quarter, defined as cash flow from operations less capital expenditures, amounted to $20 million.

    第一季營運活動產生的現金流量為3,560萬美元。第一季自由現金流量(定義為營運活動現金流量扣除資本支出)為2,000萬美元。

  • The Company repurchased approximately 31,000 shares of stock for $1.8 million during the quarter on the open market. This repurchase marked the completion of the first $100 million of the $300 million stock repurchase program we announced a year ago at this time. We expect to announce our plans for our second $100 million shortly. In this regard, I'd like to make mention of the fact that, when we file our first-quarter 10-Q, that our cash flow statement will indicate cash outlays of $14.6 million for payment of employee taxes. This figure relates to the Company's practice of issuing vested employees restricted stock, or RSUs, on a net basis, which we recently adopted for all employee stock awards. This means that instead of employees having to sell some of their vested shares to pay their payroll related taxes, the Company issues the net amount of the shares to employees and pays the payroll taxes on their behalf. So in an indirect manner, this $14.6 million should be viewed as additional stock repurchases by the Company offsetting to some extent the dilution that would otherwise have resulted from the issuance of these shares.

    本公司於本季在公開市場以180萬美元回購約31,000股股票。此次回購標誌著我們在一年前此時宣布的3億美元庫藏股回購計畫中,首個1億美元已完成。我們預期將在不久後宣布第二個1億美元的計畫。在此我想特別提及,當我們提交第一季10-Q時,現金流量表將顯示支付員工稅款的現金支出為1,460萬美元。此金額與公司做法有關:我們以淨額方式向已歸屬的員工發放限制性股票(或RSU),而我們近期已將此做法採用於所有員工股票獎酬。這表示員工不必為了支付薪資相關稅款而出售部分已歸屬股份;公司改為向員工發放扣除後的淨股數,並代員工支付薪資稅款。因此,從間接角度來看,這1,460萬美元應視為公司額外的股票回購,在一定程度上抵銷原本因發行這些股份可能造成的稀釋。

  • Cash, cash equivalents and marketable securities, including both short and long-term investments, were $613 million. This compared to $602.6 million at the end of 2014, an increase of approximately $10.4 million.

    現金、約當現金及有價證券(包含短期與長期投資)為6.13億美元。相較於2014年底的6.026億美元,約增加1,040萬美元。

  • With that, let's now turn to our business outlook for the second quarter and the factors that inform our view. Starting with the demand outlook, the second quarter has typically been a seasonally stronger period for our North American doctors and we've seen the strength of our first-quarter volume trends continuing early into the second quarter. In aggregate, we expect Invisalign volume for North America to be up sequentially in Q2.

    接下來我們來看第二季的業務展望,以及支撐我們觀點的因素。從需求展望開始,第二季通常是我們北美醫師端季節性較強的期間,而我們也看到第一季的量能趨勢在第二季初期持續強勁。整體而言,我們預期北美地區的Invisalign出貨量在第二季將較前一季成長。

  • Q2 is seasonally a busier quarter for our international doctors and we anticipate Invisalign case shipments to increase sequentially from Q1. With the recent announcement of the new iTero Element scanner which will be available in the second half of the year and the reduced pricing we have implemented on our current scanner, we anticipate some of our customers may delay purchase decisions as they evaluate choices. Therefore, we expect Q2 scanner and services revenues to be down sequentially from Q1.

    第二季在季節性上也是我們國際醫師端較為忙碌的一季,我們預期Invisalign病例出貨將較第一季增加。鑑於近期宣布的新款iTero Element掃描儀將於下半年上市,以及我們已對現行掃描儀實施降價,我們預期部分客戶在評估選項時可能會延後購買決策。因此,我們預期第二季掃描儀與服務營收將較第一季下滑。

  • With this as a backdrop, we expect the second quarter to shape up as follows. Invisalign case volume is anticipated to be in the range of 139,500 to 142,000 cases, up approximately 18% over the same period a year ago at the midpoint of the range and above our three-year average. We expect net revenues to be in the range of $206.6 million to $210.4 million, a sequential increase from Q1 primarily driven by the higher volumes just mentioned and a small price increase in North America effective April 1, each of which are partially offset again by lower ASPs, assuming a weaker euro.

    在此背景下,我們預期第二季表現如下。Invisalign病例量預估介於139,500至142,000例區間,以區間中點計較去年同期約成長18%,且高於我們三年平均水準。我們預期淨營收介於2.066億至2.104億美元,較第一季呈現季增,主要由前述較高的出貨量以及北美自4月1日起生效的小幅漲價所帶動;但假設歐元走弱,較低的平均銷售單價(ASP)將再次部分抵銷上述增幅。

  • We expect gross margin to be in the range of 75% to 75.7%, down slightly quarter-over-quarter, primarily a result of lower ASPs and a higher number of new doctor training events. We expect operating expenses to be in the range of $117.3 million to $118.3 million, a sequential increase compared to Q1, largely as a result of the benefit we recognized in Q1 for the medical excise tax refund as well as higher expenses associated with our strategic investments. Our operating margin should be in the range of 18.3% to 19.5%. Our effective tax rate should be approximately 24%. And diluted shares outstanding should be approximately $82 million, excluding any stock repurchases as mentioned earlier.

    我們預期毛利率介於75%至75.7%,較前一季略為下滑,主要因ASP較低以及新增醫師訓練活動場次增加。我們預期營業費用介於1.173億至1.183億美元,較第一季季增,主要因第一季認列醫療消費稅退稅所帶來的利益,以及與我們策略性投資相關的費用增加。我們的營業利益率應介於18.3%至19.5%。我們的有效稅率應約為24%。稀釋後流通在外股數應約為8,200萬股,不包含前述任何股票回購。

  • Taken together, we expect diluted EPS to be in the range of $0.35 to $0.38. On a constant currency basis, our Q1 average -- using Q1 average exchange rates, the Q2 outlook would've been approximately $0.02 higher.

    綜合以上,我們預期稀釋後每股盈餘(EPS)介於0.35至0.38美元。以固定匯率基礎計算,若使用第一季平均匯率,第二季展望約可再高出0.02美元。

  • With that, I will now turn the time back over to Tom for closing comments.

    接下來我把時間交回給Tom做結語。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Thanks David. We are extremely pleased to have seen strong performance in all regions getting us off to a good start to the year. In every direction we look, our strategy is working well in market expansion, as our continued investments and go-to-market initiatives deliver volume growth from better coverage and support, in product innovation as adoption growth continues to be driven by our innovation cycles for both InvisAlign and our scanner technology, and in brand strength as we reach more and more consumers, helping them connect with the right practice, ensuring they get a great InvisAlign treatment experience.

    謝謝你,David。我們非常高興看到各區域皆有強勁表現,讓我們在今年有一個良好的開局。從各個面向來看,我們的策略在市場擴張上運作良好:我們持續的投資與上市推廣(go-to-market)計畫,透過更佳的覆蓋與支援帶動量能成長;在產品創新上,InvisAlign與掃描儀技術的創新週期持續推動採用率成長;在品牌力上,我們觸及愈來愈多消費者,協助他們連結到合適的診所,確保他們獲得優質的InvisAlign治療體驗。

  • The significant growth initiatives we discussed during our year-end call include our expectations for most of the impacts showing up in our second-half results. While we are pleased to see some of that positive impact early in the new year, we do expect to see continued progress throughout 2015 as more of Align's key initiative begin to create leverage in the business.

    我們在年終法說會中討論的重大成長計畫,包括我們預期多數影響將反映在下半年業績中。雖然我們很高興在新年初期就看到部分正面影響,但我們確實預期在2015年期間將持續取得進展,因為Align的更多關鍵計畫開始在業務上產生槓桿效益。

  • There's never an ideal time for a company to have a change in the CEO role, but there are better times to make this important transition in new leadership. As we sit here today, there's clear evidence of our solid execution of Align's winning strategy, demonstrating continued and sustainable progress for the business. We have a strong leadership team and great talent across the Align organization. The Company has outstanding prospects for continued growth in revenue and earnings and expects to be a market leader for the long term. So while there's never an ideal time, this is certainly not a bad time to make this change.

    對一家公司而言,CEO職務變動從來沒有理想的時機,但在新領導層的重要交接上,確實有相對更好的時點。以我們今天所處的狀況來看,已有明確證據顯示我們對Align致勝策略的執行扎實,並展現業務持續且可延續的進展。我們擁有強大的領導團隊,以及遍布Align組織的優秀人才。公司在營收與獲利的持續成長方面前景出色,並預期長期維持市場領導地位。因此,雖然從來沒有理想時機,但現在絕對不是做出這項改變的壞時機。

  • After 13 years of leading this company and following a well-executed succession plan, this is a good time for me to step aside effective June 1. I'm extremely pleased to welcome Joe Hogan as the new President and CEO of Align Technology. Joe is a rare leader with a talent for building great teams and winning the race with a passion for customers and their patients, with the intellectual curiosity to challenge and accelerate our pace of innovation and the leadership experience to ensure this company is a market leader for the long-term. We are lucky to land him as our new CEO and he is even more excited about the opportunity to roll up his sleeves and get to work at this unique business.

    在領導公司13年並依循一套執行良好的接班計畫之後,對我而言,於6月1日起卸任是個合適的時點。我非常高興歡迎Joe Hogan出任Align Technology的新任總裁暨執行長。Joe是一位難得的領導者,擅長打造卓越團隊並以對客戶及其病患的熱情贏得競賽;同時具備求知欲,能挑戰並加速我們的創新步伐,也擁有領導經驗,確保公司長期維持市場領導地位。我們很幸運能延攬他擔任新任CEO,而他對於能在這個獨特的事業中捲起袖子投入工作更是充滿期待。

  • As for me, I'm very pleased to remain on Align's board where I will do my best to help Align flourish for many years to come. I thank you for your commitment to the Company's shareholders and for your own sense of vision about what this once struggling Silicon Valley startup could become. I have enjoyed getting to know many of you and have done my best in leading our team as we build substantial shareholder value.

    就我而言,我非常高興能繼續留在 Align 的董事會,我將盡我所能協助 Align 在未來多年持續蓬勃發展。感謝各位對公司股東的承諾,以及各位對這家曾經陷入困境的矽谷新創公司能夠成為什麼樣的企業所抱持的遠見。我很享受與各位中許多人相識的過程,也在帶領團隊、建立可觀的股東價值方面盡了最大的努力。

  • On that happy note, while I'll be signing off as your CEO in a month or so, before you let me out of here, I would guess you have a few questions for David and me on the quarter, and for Joe as to what he saw to attract them here to Align. Let's get that started. Operator?

    在這個令人愉快的時刻,雖然我將在大約一個月後卸任各位的執行長,但在你們讓我離開之前,我猜各位對本季表現應該有一些問題想問 David 和我,也想問 Joe 是看到了什麼而被吸引加入 Align。我們就開始吧。接線員?

  • Operator

    Operator

  • (Operator Instructions). John Kreger, William Blair.

    (接線員指示)。John Kreger,William Blair。

  • John Kreger - Analyst

    John Kreger - Analyst

  • Thanks very much. Joe, thanks for making time to be on the call. Could you maybe give us, as Tom suggested, a little bit of what drove your decision to join this company? It's obviously a pretty different profile from where you've been. And if you've formed them, perhaps what your first-year priorities might be?

    非常感謝。Joe,謝謝你撥空參與這通電話會議。你能否如 Tom 所建議的,跟我們分享一下是什麼促使你決定加入這家公司?這顯然與你過去所在的環境輪廓很不一樣。另外,如果你已經有初步想法,也請談談你第一年的優先事項可能會是什麼?

  • Joe Hogan - Incoming President & CEO

    Joe Hogan - Incoming President & CEO

  • I appreciate the question. Look. I'm really happy to be here. Align is a great company with a great history and good leadership and team here.

    謝謝你的提問。你看。我真的很高興能在這裡。Align 是一家很棒的公司,擁有很棒的歷史,也有良好的領導與團隊。

  • I think to your question too, I know it's smaller than what I've done in the last maybe 10 years or 12 years of my career, but honestly what I've always loved is being close to customers. I love technology. Growth in markets and customers have always been terrific for me too. And so I look at this as a chance from a career standpoint to join a winning team, a company that has a lot of growth, and also to do more of the things I really enjoy, which is the technology piece and the customer piece too. So I'm really looking forward to joining the Company.

    我想回到你的問題,我知道它的規模比我過去大概 10 年或 12 年職涯所做的要小,但老實說,我一直最喜歡的是貼近客戶。我熱愛科技。市場與客戶的成長對我而言也一直非常棒。因此我把這視為一個職涯上的機會:加入一支勝利的團隊、一家具有高度成長性的公司,同時也能多做一些我真正享受的事情,也就是科技面向與客戶面向。所以我非常期待加入公司。

  • I think the last part of your question too is, look, I see terrific trajectory here and a strong team. I don't see any reason to change that, and so I'll come on board and I'll take over the plane here and work diligently with the team to keep the momentum that Align has had over the last couple of years.

    我想你問題的最後一部分是:你看,我在這裡看到非常出色的發展軌跡與強大的團隊。我看不出有任何理由要改變這些,因此我會加入並接手這架飛機,與團隊一起勤勉合作,延續 Align 在過去幾年所累積的動能。

  • John Kreger - Analyst

    John Kreger - Analyst

  • Great, thanks. And then Tom, maybe coming back to you, now that you've got the Sirona interoperability deal in place, can you give us a sense about what does your sales force -- what are they able to do now that they've got that? Can they work collaboratively with Sirona or Patterson? Can they be knocking on the doors of existing CEREC users? How much might their approach change now that that deal is in place?

    很好,謝謝。接著 Tom,回到你這邊,既然你們已經完成與 Sirona 的互通性合作協議,你能否讓我們了解一下,你們的銷售團隊現在有了這個之後能做些什麼?他們能與 Sirona 或 Patterson 協同合作嗎?他們能去拜訪既有的 CEREC 使用者嗎?在這項協議到位後,他們的做法可能會改變多少?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Great question. I think the right touchstone is to remember that the Omnicam is starting with a pretty darn small install base to begin with, and mostly all GP dentists, and most of which do not do Invisalign today. So it does give us an opportunity to recruit great attractive practices, or if they are small Invisalign customers, you need to grow them. But we are talking a small number of thousands of units, not the bigger part of the Sirona installed base.

    好問題。我認為正確的切入點是要記得,Omnicam 一開始的裝機基礎其實相當小,而且多數都是一般牙醫(GP),其中大多數目前並沒有做 Invisalign。因此這確實給了我們一個機會去招募很優質、很有吸引力的診所;或者如果他們是小型的 Invisalign 客戶,我們就需要協助他們成長。但我們談的是幾千台的小量,而不是 Sirona 裝機基礎中更大的那一部分。

  • Longer-term, Sirona is a terrific company. They've done a great job. And I think their intentions are to turn their installed base over to Omnicam's more, and that will make that opportunity bigger. But let's just say start small and do the same things we've done with the 3M True Definition, ensure the customer has the best utility possible and we can make sure we deliver a great Invisalign experience, help the practice grow, help the patients benefit. So same approach, we'll just keep moving forward.

    從長期來看,Sirona 是一家非常出色的公司。他們做得非常好。我認為他們的意圖是讓其裝機基礎更多轉向 Omnicam,這會讓這個機會變得更大。但先從小處著手,做我們對 3M True Definition 所做的同樣事情:確保客戶能獲得最佳的使用效益,並確保我們能提供很棒的 Invisalign 體驗,協助診所成長,讓病患受益。所以方法相同,我們會持續向前推進。

  • John Kreger - Analyst

    John Kreger - Analyst

  • Great, thanks.

    很好,謝謝。

  • Operator

    Operator

  • Robert Jones, Goldman Sachs.

    Robert Jones,Goldman Sachs。

  • Robert Jones - Analyst

    Robert Jones - Analyst

  • Thanks for the questions and welcome, Joe. I look forward to working with you. Tom, I guess, on the strong growth in cases in the quarter, clearly really strong in both the GPs and Orthos in North America. I think third and fourth quarters have accelerating growth consecutively respectively. Can you maybe just share with us how much of that in your mind is the improving underlying market versus you said some early traction in the go-to-market strategy changes?

    謝謝提問,也歡迎你,Joe。我期待與你合作。Tom,我想就本季病例數的強勁成長來看,北美無論是一般牙醫(GP)或矯正醫師(Ortho)都非常強。我認為第三季與第四季的成長率分別連續加速。你能否跟我們分享一下,你認為其中有多少是基本面市場改善所帶動,對比你提到的通路策略(go-to-market)變更所帶來的一些早期成效?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • I would say yes. I don't mean to be flip, but I wish we could be very clear about exactly what the quantitative drivers were. We know that when practice flow is steady and perhaps growing a little bit and procedures, procedure mix is positive for higher value procedures, we do better than most. And we certainly had I would say steady to improving conditions as we exited 2014 and went into 2015.

    我會說是的。我不是想敷衍,但我希望我們能非常清楚地指出究竟哪些是量化的驅動因素。我們知道,當診所客流穩定、甚至略有成長,且療程、療程組合朝向更高價值的療程時,我們的表現會優於多數同業。而且我會說,當我們在 2014 年底結束並進入 2015 年時,整體環境確實是從穩定走向改善。

  • Secondly, and I'll reach back to our call at the end of the year, we were already in motion on most of these initiatives, both on the consumer side, on the product side and on the go-to-market side. So while we think of this model generally as more back-end loaded for impact and leverage, we were already seeing some positive feedback from customers in Q3 and Q4 as we've started making these changes. Better coverage, more effective coverage, better support for the practices generally means good things happen.

    第二點,我回到我們年底那次電話會議,其實我們在多數這些計畫上早已在推進中,包含消費者端、產品端以及 go-to-market 端。因此,雖然我們一般認為這個模式的影響與槓桿會較偏向後段顯現,但在我們開始做這些改變後,第三季與第四季已經從客戶那裡看到一些正向回饋。覆蓋更好、更有效的覆蓋,以及對診所更好的支援,通常就會帶來好的結果。

  • And so it's early and it's way too early to call victory here, but we think our improving capabilities and better coverage alongside a solid market is good news. We still project continued impact throughout the year as we normally see.

    所以現在還很早,遠遠不到可以宣告勝利的時候,但我們認為,在穩健的市場環境下,我們能力的提升與更好的覆蓋是好消息。我們仍預期如同以往,全年會持續看到影響逐步顯現。

  • Robert Jones - Analyst

    Robert Jones - Analyst

  • All right. So it sounds like a combination of improving markets and some of your efforts then.

    了解。所以聽起來是市場改善加上你們的一些努力共同作用。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • I think that's fair.

    我覺得這樣說很公平。

  • Robert Jones - Analyst

    Robert Jones - Analyst

  • And then I guess just sticking with North America but moving over to pricing, ASPs were down a little more than we had expected at least. I'm just curious how much leeway are you giving out there to the reps in the marketplace to drive some volume through pricing or through promotions?

    接著我想仍聚焦北美,但轉到定價來看,ASP(平均銷售價格)下滑幅度比我們預期的稍大。我想了解一下,你們在市場上給業務代表多大的空間,讓他們透過降價或促銷來帶動一些量?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Let me put this clearly. I'll let David come back to the ASP specifics. We have a series of programs. The reps have no latitude at deals or anything else. We have a very organized system of promotions we put in place usually a quarter or two in advance, and those are fairly consistent. And we have the Advantage program, which is the way we basically manage price. So there's no kind of field-based management of this per se. I'll let David maybe talk about some mix and a few other issues that contributed to some of that ASP, none of which in our minds is negative.

    我把這點講清楚。我會讓 David 回來補充 ASP 的細節。我們有一系列的方案。業務代表在交易或任何其他事項上都沒有裁量空間。我們有一套非常有組織的促銷制度,通常會提前一到兩季規劃並上線,而且相當一致。我們也有 Advantage 計畫,這基本上是我們管理價格的方式。所以嚴格來說,並不存在由前線來管理這件事。我讓 David 談談一些組合因素以及其他幾個導致 ASP 變動的議題;在我們看來,這些都不是負面的。

  • David White - CFO

    David White - CFO

  • ASPs on a worldwide basis for the quarter were primarily influenced by foreign exchange. And so we continue to believe that, as we treat more complex cases, as our international business continues to grow, we believe that our worldwide ASP should trend up, slightly up over the foreseeing future.

    本季全球 ASP 主要受到外匯的影響。因此我們仍然相信,隨著我們治療更複雜的病例、以及國際業務持續成長,我們預期全球 ASP 在可預見的未來應會呈現小幅上升趨勢。

  • Periodically, we are going to see a low volatility in that on a quarter-to-quarter basis, just dependent upon how that mix lands. This last quarter, our international business was pretty flat quarter-over-quarter seasonally, and so as a result, our lower ASPs that we typically sell under here in North America influenced that worldwide number a little bit more than what they would have otherwise.

    不過,我們會不時在季度之間看到一些小幅波動,這取決於組合如何落點。上一季,我們的國際業務在季節性因素下,與前一季相比相當持平;因此,北美這邊我們通常銷售的較低 ASP 對全球數字的影響就比原本會有的更大一些。

  • Robert Jones - Analyst

    Robert Jones - Analyst

  • Okay, so the North American then was orchestrated through some of the specific targeted promotional activity it sounds like.

    好的,所以聽起來北美當時是透過一些特定、精準鎖定的促銷活動來推動的。

  • David White - CFO

    David White - CFO

  • I don't believe that we don't normally disclose what the North America ASPs were, so I'm not sure how you are backing into that. But we didn't do anything fundamentally to change ASPs here in North America during the quarter.

    我不認為我們通常會揭露北美的ASP(平均銷售價格)是多少,所以我不太確定你是怎麼倒推出那個數字的。但我們在本季並沒有在北美做任何根本性的動作來改變ASP。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • If I can pile on for a second, if you think about that for a minute, we had great expansion in Ortho and some can I say new improving traction with GPs. When we get more high-volume doctors do more volume through the Advantage program, you're going to see a little of that in ASP. There was also a little bit of mix on the Express side, Express shift, Express mix stayed steady but a little more on Express 5. But in general nothing unusual going on and all in the direction of good.

    如果我再補充一下,稍微想一下,我們在矯正(Ortho)方面有很好的擴張,而且在一般牙醫(GP)那邊也可以說是有新的、正在改善的動能。當我們讓更多高量醫師透過Advantage計畫做更多量,你會在ASP上看到一些反映。另外在Express端也有一點組合影響,Express的轉移、Express的組合大致維持穩定,但Express 5的占比稍微多了一些。不過整體而言沒有什麼不尋常,一切都朝好的方向發展。

  • Operator

    Operator

  • Steve Beuchaw, Morgan Stanley.

    Steve Beuchaw,摩根士丹利。

  • Steve Beuchaw - Analyst

    Steve Beuchaw - Analyst

  • Good afternoon. First off, Joe, welcome to the call and thanks for taking the time to join.

    下午好。首先,Joe,歡迎加入這通電話,謝謝你撥空參與。

  • Joe Hogan - Incoming President & CEO

    Joe Hogan - Incoming President & CEO

  • Thanks Steve.

    謝謝你,Steve。

  • Steve Beuchaw - Analyst

    Steve Beuchaw - Analyst

  • And Tom, in case this is my last opportunity, thanks for everything that you have done.

    另外,Tom,如果這是我最後一次有機會,謝謝你所做的一切。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Great, Steve. It's been a pleasure working with you. I'm sure I'll see you around.

    太好了,Steve。很高興能與你合作。我相信之後還會再見到你。

  • Steve Beuchaw - Analyst

    Steve Beuchaw - Analyst

  • Hopefully in San Francisco in a few weeks.

    希望幾週後在舊金山見。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Absolutely, at AAO.

    當然,在AAO。

  • Steve Beuchaw - Analyst

    Steve Beuchaw - Analyst

  • I guess I'll start with Tom and a question following up to the question on the Sirona relationship as we think about how that rolls out over the next year or so. I wonder what you are hearing thus far, whether it's from your planning team or from the field, about how customers might take advantage of the scanner. We know in the orthodontics channel that people who have iTero, they tend to do more cases. So how are you thinking about the impact on GP customers who might have an Omnicam but not an iTero? How could their utilization evolve and how does that play out over time?

    我想先從Tom開始,延續剛才關於Sirona合作關係的問題,因為我們在思考未來一年左右這項合作如何推進。我想知道到目前為止,不論是從你們的規劃團隊或前線,你們聽到客戶可能會如何利用掃描器?我們知道在矯正通路裡,有iTero的人往往會做更多病例。那麼你們如何看待對於可能有Omnicam但沒有iTero的一般牙醫(GP)客戶的影響?他們的使用率可能如何演進,以及這在時間推移下會如何展開?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • It goes right to the point of why we are pursuing this open systems approach with interoperability. One, the scanner has to be capable, and each of our partners have had to go into investing into software and tuning their systems to work with what's a very prescribed process for Invisalign. And the Omnicam has met that standard. And when they roll out their 1.1 software, we'll be able to accept cases.

    這正切中我們為何要推動具互通性的開放系統策略。第一,掃描器必須具備足夠能力,而我們每一個合作夥伴都必須投入軟體投資並調校其系統,以符合Invisalign一套非常明確規範的流程。而Omnicam已達到該標準。當他們推出1.1版軟體時,我們就能接受病例。

  • What we would expect is whether they are low-volume Invisalign user today having to do impressions, PBS impressions to send it in, that ought to be a positive. Very few GPs, and especially a bigger office using a CEREC system for example, isn't doing a huge amount of Invisalign because they've got such a busy practice already. So we are in addition to their practice. We are not the main street part of their practice. This gives us -- this gives them an opportunity to be way more efficient, to lower their costs, and for the patient to be a whole lot happier. All of those things point to increased utilization. The result is never as significant as when you have a very high volume Ortho that immediately switches over to scanners where it really removes friction, it's very visible. So it does give us a great hunting license to go earn a bigger share of their share of mind and share of practice being even more relevant. And that's the case whether it's iTero or that's the case whether it's 3M's True Definition, and it will be the case for Omnicam. So I think, over time, our commitment is to work with each of these other players to ensure that we can deliver that great customer experience. When the patients are happy, doc is happy. We do that right, we're going to get increased adoption growth in each of these accounts over time.

    我們的預期是,對於今天仍屬低量Invisalign使用者、必須做印模、做PBS印模再寄送進來的那些人而言,這應該是正向的。很少有一般牙醫(GP),尤其是例如使用CEREC系統、規模較大的診所,會做非常大量的Invisalign,因為他們本來的門診就已經非常忙。所以我們是他們既有業務之外的增量。我們不是他們診所的主力業務。這讓我們——也讓他們——有機會大幅提升效率、降低成本,並讓病患更滿意。這些因素都指向使用率提升。其結果通常不會像高量矯正醫師(Ortho)立即改用掃描器那樣顯著,因為那種情況能立刻消除摩擦、效果非常直觀。但這確實給了我們一張很好的「狩獵執照」,去爭取更高的心佔率與診所佔比,讓我們變得更相關。不論是iTero、3M的True Definition,未來對Omnicam也會是如此。所以我認為,長期而言,我們的承諾是與這些其他業者逐一合作,確保我們能提供很棒的客戶體驗。病患滿意,醫師就滿意。我們把這件事做好,隨著時間推移,我們將在這些客戶帳戶中看到更高的採用與成長。

  • Steve Beuchaw - Analyst

    Steve Beuchaw - Analyst

  • I appreciate that. And then one for Joe. I don't think anyone can expect you to have much in the way of specifics for how you want to operate at Align at this point. But I wonder if you can reflect on your past experience with regard to building a business, a combination of organic growth and acquisitive growth, and maybe give us a sense for how you at least philosophically think about the balance there. If you have any preferences or criteria that you use to think about for capital allocation by M&A and how you think about share buybacks for a company like Align that is such a strong generator of cash. Thanks.

    我很感謝這些說明。接著問Joe一題。我想現階段沒有人會期待你對於你打算如何在Align營運有太多具體細節。但我想請你回顧一下你過去在打造事業方面的經驗——結合內生成長與併購成長——並請你分享你在理念上如何看待兩者之間的平衡。你是否有任何偏好或準則,用來思考透過併購(M&A)進行資本配置,以及對於像Align這樣現金創造能力很強的公司,你如何看待庫藏股(share buybacks)?謝謝。

  • Joe Hogan - Incoming President & CEO

    Joe Hogan - Incoming President & CEO

  • I can read through your question. I've done a lot of M&A in my life and I'm sometimes labeled as an M&A person. But I can tell you that I've only done that in the sense of looking at what organic growth is in different businesses I've been in. And 10 to 1, I'd rather grow organically than look at acquisitions. But every role that I've been in, whether was running business within GE or most recently ABB, I don't really come in with a playbook. I come in and just see what the company does well and where it might need help, assess the team and understand the team and the strength of that team and then look to figure out how to grow and how to operate well. So I don't really have a playbook in that sense.

    我理解你的問題。我人生中做過很多併購,有時也被貼上「併購型人物」的標籤。但我可以告訴你,我之所以會做那些,是因為我會先看我所在的不同事業其內生成長的狀況。十次有九次,我寧可選擇內生成長,也不會去看收購。但我在每一個角色,不論是在GE負責某個事業,或最近在ABB,我其實不會帶著一套既定劇本進來。我會先看看公司擅長什麼、哪裡可能需要協助,評估團隊、了解團隊以及團隊的強項,然後再去思考如何成長、如何把營運做好。所以在那個意義上,我並沒有一套固定劇本。

  • I think that if you go back through my history, and I know several people out there have contacted so my friends and different people, which I appreciate, you get idea of from them rather directly for me but indirectly from them how they felt about working with me or for me. Hopefully, you will hear that. So honestly I come in here. I see a team that has an incredible track record, tremendous leadership by Tom, a business that has incredible potential in a lot of ways, whether it's scale or through additional technology and some of the things that David and Tom just talked about. And I look to see how we can enhance that. And obviously as I start and look at the company, I'll get out and see customers, I'll meet as much of the company as I can, and then from there we will figure out what we need to do to grow more and what makes the most sense.

    我想如果你回頭看我的經歷,而且我知道外面有幾位已經去聯絡了我的朋友和不同的人——我很感謝——你會從他們那裡得到一些想法:不是直接從我,而是透過他們間接了解他們與我共事或在我麾下工作的感受。希望你會聽到那些回饋。所以老實說,我來到這裡,我看到的是一個有著驚人績效紀錄的團隊、Tom卓越的領導,以及一個在很多面向都具有巨大潛力的事業,不論是規模化,或是透過額外技術,以及David和Tom剛才談到的一些事情。而我會去看我們如何能強化這些。當然,隨著我開始並深入了解公司,我會出去拜訪客戶、盡可能認識公司內更多人,然後從那裡我們會找出需要做什麼才能成長得更多,以及什麼做法最合理。

  • Steve Beuchaw - Analyst

    Steve Beuchaw - Analyst

  • That's really helpful. Thanks so much.

    這真的很有幫助。非常感謝。

  • Operator

    Operator

  • Chris Lewis, ROTH Capital.

    Chris Lewis,ROTH Capital。

  • Chris Lewis - Analyst

    Chris Lewis - Analyst

  • Hey guys. Thanks for taking the questions. And Joe, welcome and thanks for taking the time to be on the call today.

    嗨,各位。謝謝讓我提問。Joe,歡迎你,也謝謝你今天撥空參與這通電話。

  • I just wanted to start on the gross margins. And I may have missed it but it looks like it came in about 300 basis points above your outlook. So can you elaborate on what drove the upside for gross margin during the quarter in the face of FX headwinds? And then as you look into the second quarter, what are the factors that are leading to your expectation for a sequential decline in gross margin in the second quarter?

    我想先從毛利率開始問。我可能漏聽了,但看起來實際結果比你們的展望高了大約300個基點。所以能否說明一下,在面臨匯率(FX)逆風的情況下,本季毛利率優於預期的驅動因素是什麼?另外,展望第二季,你們預期毛利率將季對季下滑,背後有哪些因素?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • One of the phenomena about our business has to do with the training events that go on from period to period. And in periods when we have more training events than other periods, our margins tend to fluctuate in the down direction or in the up direction depending upon whether those training events are increasing or decreasing. And so when you look from Q4 to Q1, the training events were down in Q1, and we are anticipating they're going to be back up in Q2. And that certainly has some influence on it. When you look at the Q2 guidance, part of it is foreign exchange rates have moved another 5 points on us since the last -- well, since Q1 average. So that has obviously some bearing on the margin guidance we gave for Q2.

    關於我們業務的一個現象,與各期之間持續進行的培訓活動有關。在某些期間我們的培訓活動比其他期間更多時,我們的利潤率往往會隨著培訓活動是增加或減少,而向下或向上波動。因此,從第四季到第一季來看,第一季的培訓活動減少,而我們預期第二季會回升。這當然對此有一定影響。再看第二季的指引,其中一部分原因是外匯匯率自上次——嗯,自第一季平均水準以來——又對我們不利地變動了5個點。所以這顯然也會影響我們給出的第二季利潤率指引。

  • Chris Lewis - Analyst

    Chris Lewis - Analyst

  • Okay. Great. That's helpful.

    好的。很好。這很有幫助。

  • David White - CFO

    David White - CFO

  • If I could add, we had increased volumes in the business. We had good performance in management of direct cost by the team. So we've seen where we put volume into this business, it shows up in a variety of ways.

    如果我可以補充一下,我們的業務量有所增加。團隊在直接成本管理方面表現良好。因此我們看到,當我們把量導入這項業務時,它會以多種方式反映出來。

  • Chris Lewis - Analyst

    Chris Lewis - Analyst

  • Understood. And then in terms of the high teen volume growth outlook you provided on the last call, 17% year-over-year volume growth this quarter, 18% guided to the midpoint next quarter, can you just talk about how you're feeling you're tracking towards that high teen volume growth outlook at this point, given you're already kind of there in the first and second quarter and you talked about further impact from the North American go-to-market approach in the back half of this year?

    了解。接著,關於你們在上次電話會議中提供的「高十幾%」的量成長展望,本季年增17%的量成長、下季指引中點為18%,你們能否談談就目前而言,你們對於達成這個高十幾%量成長展望的進度感受如何?畢竟你們在第一季和第二季已經差不多達到這個水準,而且你們也提到今年下半年北美市場推進(go-to-market)策略還會帶來進一步影響。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • David is the one providing the guidance, so I'll turn it over to him. But I'll start by saying all the elements we've talked about that we tested during fiscal year 2014 and pretty much had in place, we were getting good feedback. We said it was very early in the year at the end of January to see but we are getting good feedback from customers, that they felt the coverage should improve, our responsiveness was improving. We were in better position to help them be successful in their practices, I would say maturation of things like deep bite and some of the initiatives we've been working on for a while, all those things kind of started to come together with a great consumer program. So pleased that our innovation cycle coverage and go-to-market adjustments around the world and now in North America a little more, and consumer programs kind of work together.

    指引是David提供的,所以我把問題交給他。不過我先說,我們在2014財年測試、並且幾乎都已到位的各項要素,我們收到了很好的回饋。我們在一月底時說過,年初還很早、還看不太出來,但我們確實從客戶那裡得到很好的回饋:他們覺得覆蓋度應該會提升、我們的回應速度也在改善。我們更有能力協助他們在診所營運上取得成功;我會說,像深咬(deep bite)之類的成熟度,以及我們已經推動一段時間的一些計畫,這些都開始與一個很棒的消費者方案一起匯聚成效。因此我們很高興,我們的創新週期覆蓋、全球的市場推進調整、以及現在在北美更進一步的調整,再加上消費者方案,能夠一起發揮作用。

  • And again, I'd say the backdrop is a reasonably healthy market, but we've been reasonably comfortable that we are on the right track. Again, the tide can go out a little bit, but I think we're going to do better than most.

    再說一次,我認為大環境是一個相對健康的市場,但我們一直相當有信心我們走在正確的軌道上。當然,潮水可能會稍微退一些,但我認為我們會比大多數同業做得更好。

  • I'll let David come back and comment specifically on the framework he provided for the year.

    我讓David回來,針對他為全年提供的框架做更具體的評論。

  • David White - CFO

    David White - CFO

  • Yes, so Chris, when we gave the framework back in January and so forth, we had obviously a lot of lifting to do against the foreign exchange headwinds and so forth. We had a lot of investments we were making to hopefully drive topline in not only the long-term but certainly in the short-term. And you may recall in our comments I think we might even have mentioned something to that effect here earlier in the call, that we expect to see more of our growth coming in the second half of the year as some of those investments begin to take hold. So, as we think about the year in totality, we feel like we've gotten off to a great start. And here we are sitting in April feeling good about that but we also know we have a lot of work still left ahead of us to deliver the full-year results that we gave you the outlook on just a couple of months ago.

    是的,所以Chris,當我們在一月提出那個框架等等時,我們顯然需要做很多努力來對抗外匯逆風等等。我們也做了很多投資,希望不僅在長期、當然也在短期內推動營收成長。你可能還記得我們的評論——我想我們甚至可能在本次電話會議稍早也提到過——我們預期隨著部分投資開始發揮效果,更多的成長會出現在下半年。因此,當我們從全年整體來看,我們覺得開局非常好。現在四月,我們對此感覺良好,但我們也知道,為了交出幾個月前給你們的全年展望結果,我們前面仍有很多工作要做。

  • Chris Lewis - Analyst

    Chris Lewis - Analyst

  • Great. Tom, just wanted to congratulate you on a great run, and wish you all the best going forward. Thanks.

    很好。Tom,只是想恭喜你一路走來表現出色,也祝你未來一切順利。謝謝。

  • Operator

    Operator

  • Jeff Johnson, Robert W. Baird.

    Jeff Johnson,Robert W. Baird。

  • Jeff Johnson - Analyst

    Jeff Johnson - Analyst

  • Thank you. Good evening, guys, and welcome Joe and Tom. Hopefully I'll catch you in San Francisco in a couple weeks like some of the others.

    謝謝。各位晚安,也歡迎Joe和Tom。希望我能像其他人一樣,幾週後在舊金山見到你們。

  • I wanted to start, Joe, you made a comment that some of us have been out there checking on you and one of the labels that gets put on you is maybe an M&A focus. One of the other labels, if I want to phrase it that way, is that you may be a very cost-conscious or cost-focused kind of guy as well. Maybe that stems obviously from your GE Healthcare days. But just in general, how do you think about costs? And you're running obviously a growth company, a West Coast-based growth company. Any comments you could make on that side of the story?

    我想先從Joe開始,你提到我們當中有些人一直在外面關注你,而貼在你身上的其中一個標籤可能是偏重併購(M&A)。另一個標籤——如果我可以這樣說——是你可能也是一個非常重視成本、或以成本為導向的人。這或許顯然源自你在GE Healthcare的經歷。但總體而言,你如何看待成本?而你顯然是在經營一家成長型公司,一家位於西岸的成長型公司。你能否就這一面談談你的看法?

  • Joe Hogan - Incoming President & CEO

    Joe Hogan - Incoming President & CEO

  • That's a really good question. In my career, I've had to understand operations and be part of operations or whatever. One of the reasons I'm here is because I love growth and I love businesses that have the potential to grow. And obviously investment in growth is a real important thing. I think when you listen to Tom and David, I smile because you can see a good input-output ratio in the sense of what investments are being made here and the consequential growth you can get in a relatively shorter period of time. And so hopefully you can see in the sense of the business that that works. And I like things that work in a business and what levers you pull and how things work.

    這是個非常好的問題。在我的職涯中,我必須理解營運並參與營運等等。我來到這裡的原因之一,是因為我熱愛成長,也熱愛具有成長潛力的企業。而且很明顯,對成長的投資是一件非常重要的事。我聽Tom和David在講時會微笑,因為你可以看到很好的投入—產出比:在這裡做了哪些投資,以及在相對較短時間內能帶來的相應成長。所以希望你能從業務的角度看到這是有效的。我喜歡在企業中有效的事情——你拉動哪些槓桿、事情如何運作。

  • Secondly, from a cost standpoint, I'm a guy who wants to understand costs make sure when you do make investments, that they are good investments. You just don't take that for granted. And so I also need to be diligent around cost and really understand where it's going. And often from a portfolio standpoint, you might want to make some -- move something from one part of the business to another part to see if you can actually grow more. So I don't think it's a liability at all but I understand operations and enjoy operations, but don't look at it in a sense of just from a standpoint of cost, saving cost. It's just an allocation of capital and resources and where that best goes in a business at any point in time. I hope that makes sense.

    第二,從成本角度來看,我是一個想要理解成本的人,並確保當你做投資時,那些都是好的投資。你不能把這件事視為理所當然。因此我也需要在成本上保持嚴謹,真正了解成本流向何處。而且從投資組合的角度,你可能會想做一些——把某些資源從業務的一部分移到另一部分,看看是否能實際帶來更高的成長。所以我不認為這是負擔;我理解營運、也享受營運,但我不會只從節省成本、削減成本的角度來看。這更像是資本與資源的配置,以及在任何時間點,這些資源在企業中最適合投向哪裡。希望這樣說得通。

  • Jeff Johnson - Analyst

    Jeff Johnson - Analyst

  • It does. Very helpful as well, thank you. David, one question for you and I'll take kind of maybe the opposite side of Bob's question earlier. On ASPs, the sequential decline of $35 was actually less than we were thinking it was going to be; the decline was less. So ASPs came in a bit above what we were thinking. And you said 90% of that was currency. When I look at the GP number, GP up 6.5% was a decently good number, better than it's been, but stacked comps still got a little slower.

    說得通。也非常有幫助,謝謝。David,我有一個問題要問你,我會從Bob剛才問題的另一面來看。關於ASP,連續下滑35美元其實比我們原先預期的要少;下滑幅度較小。所以ASP略高於我們的預期。而你說其中90%是匯率因素。當我看毛利(GP)數字,毛利成長6.5%算是相當不錯,比之前好,但疊加比較基期(stacked comps)仍然稍微放慢。

  • So I guess what I'm trying to figure out is you had a sizable Express 5 promotion in place this quarter. Has that just not generated the traction yet? Should we think about kind of the acceleration off that promotion kind of coming more in Q2 and I would assume that would then impact the ASPs a little bit more in 2Q over the 1Q as well?

    所以我想弄清楚的是:你們本季有一個規模不小的Express 5促銷活動。這是否只是尚未帶來足夠的拉動效果?我們是否應該預期該促銷帶來的加速會更多出現在第二季?而我假設那也會讓第二季的ASP相較第一季再多一些影響?

  • David White - CFO

    David White - CFO

  • Specifically regarding the Express promotion, we implemented that in the middle of the quarter. And then you have to recognize that it's going to take a while before doctors are going to get engaged with that promotion. It's going to take a while for them to get patients in the seat, to get them through treatment planning, get treatment planning approved, fabricate the aligners, etc., so we only saw a small impact of Express 5 really during Q1. We are continuing that promotion into Q2, and so to the extent that has some impact on ASPs, we think it will be relatively modest.

    就 Express 促銷而言,我們是在本季中段推出的。接著你必須認知到,醫師要投入並參與這項促銷需要一些時間。他們需要時間把病人安排就座、完成治療規劃、讓治療規劃獲得核准、製作隱形牙套等等,因此我們在第一季其實只看到 Express 5 的小幅影響。我們會在第二季持續這項促銷,因此若它對 ASP(平均銷售價格)有些影響,我們認為幅度會相對溫和。

  • And I'd say the other thing is that our objective with the Express 5 promotion is to drive adoption. And we kind of view the Express 5 promotion as a way to increase the volumes that we would've otherwise done as a company in any event. So we see the Express 5 promotion really as incremental. It will have -- to the extent it was wildly successful, which we will certainly hope for, that would have some impact on ASPs but we are not expecting it to be that meaningful.

    另外我想說的是,我們推出 Express 5 促銷的目標是推動採用率。我們某種程度上把 Express 5 促銷視為一種方式,用來提升公司原本無論如何都會做到的量。所以我們認為 Express 5 促銷確實是增量貢獻。若它——在它非常成功的情況下(我們當然希望如此)——可能會對 ASP 造成一些影響,但我們不預期會有那麼顯著。

  • Jeff Johnson - Analyst

    Jeff Johnson - Analyst

  • Understood.

    了解。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • If I may add to that, I'll point you back to what I said earlier. This is about really getting progress and greater adoption by the core customer group we want, orthos and GPs that have made it a big part of their practice. And when that happens, they get a little better pricing. There's a little more our total volume going through Advantage and we would expect a little bit of a move on ASP down. But that's a really good bet because we are most efficient covering those customers versus bringing a very low volume customer along where there is very low leverage in the go-to-market model. So we've always been very willing to have that volume impact for a fairly modest ASP decline. So that's -- in our minds that's progress.

    如果我可以補充一下,我想請你回想我先前說過的。這主要是要讓我們想要的核心客群——把它作為其診所很大一部分的矯正科醫師與一般牙醫(GP)——取得進展並提高採用率。當這件事發生時,他們會拿到稍微更好的價格。我們透過 Advantage 的總量會多一些,而我們預期 ASP 會有些下移。但這其實是很划算的取捨,因為相較於帶動一個量非常低的客戶(在 go-to-market 模式中槓桿很低),我們覆蓋這些客戶的效率最高。所以我們一直都很願意用相當溫和的 ASP 下滑,來換取這樣的量的影響。所以——在我們看來,這就是進展。

  • Jeff Johnson - Analyst

    Jeff Johnson - Analyst

  • Yes. I got it. Not a criticism of the program at all. Just wanted to check when the impact would come down.

    是的。我明白了。我完全不是在批評這個方案。只是想確認影響大概什麼時候會反映出來。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • We didn't take it that way, just trying to be clear.

    我們沒有那樣理解,只是想把事情講清楚。

  • Jeff Johnson - Analyst

    Jeff Johnson - Analyst

  • Thank you. I appreciate it.

    謝謝。我很感激。

  • Operator

    Operator

  • Jon Block, Stifel.

    Jon Block,Stifel。

  • Jon Block - Analyst

    Jon Block - Analyst

  • Great. Thanks and good afternoon. I'll preface this by saying, trying to be clear not that I'm complaining, but when the Company (technical difficulty) when you guys complete those case volumes in conjunction with Tom's retirement, if I remember correctly, that was at the very end of March. I think like the 25th or the 26th. And sort of the wording in that release would have implied around 127,000, 128,000 1Q cases. You did close to 131,000. I mean the way your revenue model works, the quarter was closed back then. So I'm just asking, David, I guess this one's for you. Can you explain that discrepancy? And then Tom, as a function of that, maybe if you can comment on intra-quarter trends that you saw and more specifically how you exited March and April?

    很好。謝謝,午安。我先說在前面,想把話講清楚,我不是在抱怨,但當公司(技術問題)當你們在 Tom 退休的同時完成那些病例量時,如果我沒記錯,那是在三月底的最後幾天。我記得大概是 25 或 26 號。而那份新聞稿的措辭似乎暗示第一季病例約 127,000、128,000 例左右。但你們做了接近 131,000 例。以你們的營收模型來看,那時候季度其實已經關帳了。所以我只是想問,David,我想這題是問你的。你能解釋一下這個落差嗎?然後 Tom,基於這點,也許你可以談談你看到的季內趨勢,尤其是三月收尾以及四月開局的情況?

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • I am going to get in front of David for one reason. This was not a going away gift for me. This is the way the business evolved and trying to meet customer needs. It's really, really simple and the way the volume flowed through the quarter was pretty linear, but it was just to meet our kind of -- our standard requirements, we wanted to get those cases out. We're not trying to micromanage that. And again, we had some work to do while we were coming out with his news on me. I'll let David talk to you.

    我先在 David 前面回答一點,原因只有一個。這不是給我的離職禮物。這就是業務演進的方式,也是為了滿足客戶需求。其實非常、非常簡單,本季量的流動相當線性,但只是為了符合我們一貫的——我們的標準要求,我們希望把那些病例交付出去。我們並不想對此進行微觀管理。而且再說一次,在我們對外發布我這個消息時,我們還有一些工作要做。我讓 David 來跟你說。

  • David White - CFO

    David White - CFO

  • I think we only really -- I think the press release, I don't know the exact wording in it, Jon, but I think it said we expected to be slightly above the high end of our range. And I guess you can define what "slightly" means, but the only other alternative would've been to put a number of there, and we just didn't feel that was the right thing to do. I think we gave you the best guidance we could in terms of the appropriateness of what we put in a press release before we are ready to close out the financials and talk about it a few weeks later.

    我想我們其實只是——我不確定新聞稿的確切措辭,Jon,但我想它是說我們預期會略高於我們區間的上緣。而你可以自行定義「略」是什麼意思,但另一個選項就是直接給一個數字,而我們不覺得那是正確的做法。我認為在我們尚未準備好結帳並在幾週後談財務數字之前,就新聞稿而言,我們已經提供了我們能給的最佳指引。

  • Jon Block - Analyst

    Jon Block - Analyst

  • Fair enough. And again, not that I'm complaining.

    可以接受。而且再說一次,我不是在抱怨。

  • Question two, if I can just have sort of a call it part A and part B. The first one, part A, David, longer-term, that 25% to 30% sort of three- to five-year op margin goal, should we think about that and normalize for FX? And I know you don't want that sort of a moving target and floating daily to currencies, but that should be down maybe 200 to 300 basis points from when you gave that last year at the analyst day. So should we think of that more 22% to 27%, or how should we flow that through our model?

    第二個問題,如果可以的話我想分成 A 與 B 兩部分。第一個,A 部分,David,長期來看,那個 25% 到 30% 的三到五年營業利益率目標,我們是否應該以剔除匯率(FX)影響後來看?我知道你不希望它變成一個會隨匯率每天浮動的移動目標,但相較於你去年分析師日給的目標,這可能要低個 200 到 300 個基點。所以我們應該把它理解成 22% 到 27% 嗎?或我們應該如何把這個納入模型?

  • And then Tom, the B is I'm sort of trying end our interaction with a difficult question. On the Sirona deal, which still, in my opinion, came two years too late, but to dig deeper, why not make that exclusive and have something where you have a payment flowing from you guys to Sirona so when you fast-forward three years, they can't sign up a DENTSPLY or a Danaher and lock up that volume on Invisalign's platform. Thank you guys.

    然後 Tom,B 部分是,我想用一個比較尖銳的問題來結束我們的互動。關於 Sirona 的合作案,在我看來仍然晚了兩年,但更深入地問,為什麼不把它做成獨家,並設計成你們付費給 Sirona 的安排,這樣三年後他們就不能再簽下 DENTSPLY 或 Danaher,並把那個量鎖在 Invisalign 的平台上?謝謝各位。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • I think that's a four-part question, John. Let me start first with the whole logic for being an open systems. Simply stated, it's better for our customers. No one wants to have to redesign, start over, buy multiple pieces of equipment if they can have greatest utility from a scanner. By the way, with this open systems, we still sell more standalone scanners than anybody else. So we are doing pretty well even as we're opening up Invisalign, which would be an advantage for our iTero team to sell our own scanner. So, we believe what we hear from our customers is they don't want to be forced to buy a system from you for the pleasure of offering Invisalign to their patients and other therapies we may have down the road. So we feel actually very strongly.

    我覺得那是四個問題,John。我先從採用開放系統的整體邏輯談起。簡單說,這對我們的客戶更好。如果能讓掃描器發揮最大效用,沒有人想要為了這件事去重新設計、從頭開始、或購買多套設備。順帶一提,在這個開放系統下,我們仍然賣出比任何人都多的獨立式掃描器。所以即便我們在開放 Invisalign(這原本會是我們 iTero 團隊銷售自家掃描器的一項優勢),我們的表現仍然相當不錯。因此,我們相信從客戶那裡聽到的是:他們不希望被迫為了能向病人提供 Invisalign,以及我們未來可能推出的其他療法,而必須向你購買一整套系統。所以我們其實非常堅定。

  • To the point of paying Sirona, this is really about value creation for our customer. Most buyers of scanners say they want to make sure the scanner can do a therapy like Invisalign. So if anybody was going to pay, it ought to be the other way around.

    至於付費給 Sirona 這點,這其實是為客戶創造價值。多數掃描器買家表示,他們希望確保掃描器能支援像 Invisalign 這樣的療程。所以如果真的有人要付費,那也應該是反過來才對。

  • As to exclusivity, we think that everybody brings a different story to the market. Sirona has a great product offering with restorative dentistry. Patterson carries a lot of products. They are focused for that. There's no reason -- we don't really directly compete with them. There's no reason for us not to act in complementary ways because it's good for the customer. So in our minds, we don't need to own the channel. We don't need to have exclusivity. In fact, we want probably more high-quality scanners that can make it easier to do Invisalign and other chair-side procedures that we have the unique capabilities to fulfill. So I think I would point you in the opposite direction. There's more benefit from giving the customer what they want at a lower cost and greater utility over time than anything else.

    就獨家性而言,我們認為每個人都會為市場帶來不同的故事。Sirona 在修復牙科方面有很棒的產品組合。Patterson 經銷很多產品。他們專注於此。沒有理由——我們其實不會直接與他們競爭。我們沒有理由不以互補的方式合作,因為這對客戶有利。所以在我們看來,我們不需要擁有這個通路。我們不需要獨家性。事實上,我們可能希望有更多高品質的掃描器,讓 Invisalign 以及我們具備獨特能力可完成的其他椅旁(chair-side)程序更容易進行。所以我想我會把你引導到相反的方向。相較於其他任何事情,讓客戶以更低成本、並在時間推移中獲得更高效用地得到他們想要的東西,帶來的好處更大。

  • Jon Block - Analyst

    Jon Block - Analyst

  • Fair enough. David, can I get you to comment on the three- to five-year outlook you guided?

    可以理解。David,我可以請你評論一下你所給出的三到五年展望指引嗎?

  • David White - CFO

    David White - CFO

  • Jon, our operating model that we've been targeting and striving to achieve for some time is certainly influenced by a lot of variables, FX being just one of them. We've showed and I think we've demonstrated the leverage we get out of our business model in the last year, 2014 being the first year that we actually landed results inside that model. And so we do get leverage from growth. And growth is the best strategy for growing out of the headwinds we are getting from FX. And so while those headwinds may set us back a little bit while we try and readjust our business and so forth, I think the great thing about our business is the fact that it's growing and as we continue to grow, particularly on the international side, we believe we can grow out of those currency headwinds. And so we don't see any reason to update our model. I think it's still -- it's a long-term model. It's still aspirational in some respects. And we still feel pretty strongly about the potential of the business to grow into it, again, even with the headwinds.

    Jon,我們一直以來鎖定並努力達成的營運模型,確實會受到許多變數影響,外匯(FX)只是其中之一。我們已經展現、我想也已經證明了在過去一年中我們的商業模式所帶來的槓桿效應;2014 年是我們首次真正把結果落在該模型範圍內的一年。因此,我們確實能從成長中獲得槓桿效益。而成長是用來走出外匯逆風的最佳策略。所以,雖然這些逆風可能會在我們嘗試重新調整業務等過程中讓我們稍微落後一些,但我認為我們業務最棒的一點在於它正在成長;而且隨著我們持續成長,特別是在國際市場方面,我們相信可以透過成長來抵消這些匯率逆風。因此,我們看不出有任何理由要更新我們的模型。我認為它仍然——是一個長期模型。在某些方面它仍帶有願景性(aspirational)。而我們仍然相當有信心,業務有潛力成長並逐步符合該模型的目標,即使仍面臨逆風也是如此。

  • Jon Block - Analyst

    Jon Block - Analyst

  • Perfect. Thanks.

    太好了。謝謝。

  • Operator

    Operator

  • Glen Santangelo, Credit Suisse.

    Glen Santangelo,瑞士信貸(Credit Suisse)。

  • Glen Santangelo - Analyst

    Glen Santangelo - Analyst

  • Thanks. Tom and David, last quarter, we spent a fair amount of time talking about some of the incremental investments that you plan to make around areas of sleep apnea, the new ERP system, some of the North American salespeople. And at that time, you gave some pretty specific details around that and the potential impacts it might have on margin. Maybe could you give us a little bit of an update there, maybe give us a sense for maybe how much you might have spent in those areas this quarter and what you're forecasting to spend in the second quarter?

    謝謝。Tom 和 David,上個季度我們花了不少時間討論你們計畫在睡眠呼吸中止症、新的 ERP 系統、以及一些北美銷售人員等領域進行的增量投資。當時你們提供了相當具體的細節,以及這些投資可能對毛利率/利潤率造成的影響。你們能否在這裡給我們一點更新,例如這一季在那些領域大概花了多少,以及你們預估第二季會花多少?

  • David White - CFO

    David White - CFO

  • Yes, Glen, I don't know that I really got an update for you. I think, when we gave the outlook for the year, and as you see our first-quarter results and our guidance for Q2, I think you can see the uplift in our operating expenses. I think you can assume that all of -- most of that uplift has to do with new investments. We talked about sleep apnea in Q1. We talked about the investments in the sales force and go-to-market coverage, etc. Those investments are all P&L investments. So I think it's pretty transparent, when you look at our Q1 results and our guidance, that those investments are proceeding as we indicated. And I think they will continue to proceed throughout the balance of the year as we continue to plant seeds for the future direction and the growth of the business.

    是的,Glen,我不確定我是否真的有什麼更新可以提供。我想,當我們給出全年展望時,結合你看到的第一季結果以及我們對第二季(Q2)的指引,你應該可以看到營運費用的上升。我想你可以假設其中全部——或大部分的上升都與新的投資有關。我們在第一季談到了睡眠呼吸中止症。我們也談到了對銷售團隊與市場進入(go-to-market)覆蓋等方面的投資。這些投資都是損益表(P&L)上的投資。所以我認為,當你看我們第一季結果與指引時,這些投資正如我們所說的那樣在推進,這點相當透明。而且我認為,隨著我們持續為未來方向與業務成長播下種子,這些投資在今年剩餘期間也會持續推進。

  • Glen Santangelo - Analyst

    Glen Santangelo - Analyst

  • Okay. That's fine. Maybe if I can just ask Joe a question. Joe, it kind of sounds like you're excited about a bunch of the opportunities that you see. But one of the issues that's been on investors' minds is around intellectual property and the expiration of some of the patents in 2017 and 2018. And so I'm kind of curious. Could you maybe share with us how much due diligence you did around this IP issue, and how maybe you got comfortable with this issue when considering taking the position?

    好的。沒問題。也許我可以再問 Joe 一個問題。Joe,聽起來你對你所看到的一系列機會感到很興奮。但投資人一直關心的一個議題是智慧財產權,以及 2017 年和 2018 年部分專利到期的問題。所以我有點好奇。你能否跟我們分享一下,你針對這個 IP 議題做了多少盡職調查,以及在考慮接任這個職位時,你是如何對這個議題感到放心的?

  • Joe Hogan - Incoming President & CEO

    Joe Hogan - Incoming President & CEO

  • I think that's a good question. Honestly, my due diligence was almost with a you to receive from Tom and the rest of the team and looking at what's going on. If you look at the R&D investment and the number of patents, and you look at the sequential technology capability that Align has really shown through these investments, starting with relatively simple kind of aligners and through the years becoming more and more capable of doing more difficult cases, I think shows that overall the initial expiration of those patents in a few years forward, there's more to this than just a couple of patents coming off in the sense of the success here in what's been done.

    我覺得這是個好問題。老實說,我的盡職調查幾乎是與你們相同——從 Tom 和團隊其他成員那裡接收資訊並觀察正在發生的事情。如果你看研發(R&D)投入和專利數量,再看 Align 透過這些投資所展現的連續性技術能力——從相對簡單的矯正器開始,這些年來變得越來越有能力處理更困難的病例——我認為這顯示出,幾年後那些專利的初始到期,整體而言不只是幾項專利到期這麼簡單;就已完成的成果與成功而言,背後還有更多因素。

  • So, obviously, in my life, I've been associated with a lot of IP, particularly with GE Medical and GE Healthcare. I understand the impact of customer preference, also market channeling, skill, all those things as it relates to IP too. When I look at Align, I see there's much more going on here than just the patents coming off in the next couple of years and the sense of the momentum of what the opportunity is too. That's not to negate what that might mean from a competitive standpoint, but everyone has competition. Competition should make you better and companies be able to respond to that too. And I think Align has shown that they can do that. As I take over for Tom and we work as a team, we'll continue to focus on customers, we'll continue to invest in R&D, will continue to scale globally, and I think that's going to help that whole equation a lot.

    所以,很明顯地,在我的職涯中,我與許多 IP 有關聯,特別是在 GE Medical 和 GE Healthcare。我理解客戶偏好、以及市場通路導向、技能等所有這些因素,與 IP 的關聯與影響。當我看 Align 時,我看到這裡正在發生的事情遠不只是未來幾年專利到期而已,還包括機會所帶來的動能。這並不是要否定從競爭角度來看那可能意味著什麼,但每個人都有競爭。競爭應該讓你變得更好,而公司也應該能夠對此做出回應。我認為 Align 已經證明他們能做到。當我接替 Tom、並且我們以團隊方式合作時,我們會持續聚焦客戶、持續投資研發、持續在全球擴張規模,我認為這將對整個方程式有很大幫助。

  • Glen Santangelo - Analyst

    Glen Santangelo - Analyst

  • Okay. Thanks for the comments.

    好的。謝謝你的評論。

  • Operator

    Operator

  • Jeffrey Matthews, Ram Partners.

    Jeffrey Matthews,Ram Partners。

  • Jeffrey Matthews - Analyst

    Jeffrey Matthews - Analyst

  • Hi. Joe, I just want to say I look forward to meeting you. My old pal Nat Kingman speaks very highly of you. And Tom, I don't want to offend any of the sports fans on the call, but I feel like I did when Mariano Rivera retired from the Yankees. Very sad but very appreciative of his track record. And I just want to say congratulations and great good luck. You deserve all good things.

    嗨。Joe,我只是想說我很期待與你見面。我的老朋友 Nat Kingman 對你評價很高。Tom,我不想冒犯電話會議上的任何運動迷,但我感覺就像 Mariano Rivera 從洋基隊退休時一樣。非常難過,但也非常感謝他一路以來的成績紀錄。我只想說恭喜你,並祝你一切順利、好運。你值得擁有所有美好的事物。

  • Tom Prescott - Director, President, CEO

    Tom Prescott - Director, President, CEO

  • Very nice of you to say, appreciate it.

    你這麼說真是太好了,感謝你。

  • Shirley Stacy - VP IR & Corporate Communications

    Shirley Stacy - VP IR & Corporate Communications

  • Thank you, everyone, for joining us. That concludes our conference call today. We look forward to seeing you at upcoming conferences and industry meetings. If you have any follow-up questions, please contact Investor Relations. Have a great day.

    感謝各位加入我們。今天的電話會議到此結束。我們期待在接下來的各項會議與產業聚會上與各位見面。如有任何後續問題,請聯絡投資人關係部門。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's teleconference. You may disconnect your lines at this time and we thank you for your participation.

    今天的電話會議到此結束。您現在可以掛斷電話線,並感謝您的參與。